CAL
BPMC

Capital Advisors Ltd’s Blueprint Medicines BPMC Stock Holding History

Capital Advisors Ltd’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed – – 1365
2025
Q2 		$0 Hold
3
– – ﹤0.01% 1355
2025
Q1 		$0 Hold
3
– – ﹤0.01% 1355
2024
Q4 		$0 Hold
3
– – ﹤0.01% 1386
2024
Q3 		$0 Hold
3
– – ﹤0.01% 1389
2024
Q2 		$0 Hold
3
– – ﹤0.01% 1395
2024
Q1 		$0 Hold
3
– – ﹤0.01% 1367
2023
Q4 		$0 Buy
+3
New +$194 ﹤0.01% 1303

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capital Advisors Ltd's BPMC Position: Q3 2025 in Review

Capital Advisors Ltd sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3 shares.

Capital Advisors Ltd first reported a position in BPMC in Q4 2023 and held it in 7 quarters. The position peaked at $0 in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Capital Advisors Ltd reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 3 Blueprint Medicines shares in Q3 2025.
  • Capital Advisors Ltd first reported a position in Blueprint Medicines in Q4 2023 and held it in 7 quarters.
  • Capital Advisors Ltd's Blueprint Medicines position peaked at $0 in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Capital Advisors Ltd's 13F filing for Q3 2025, filed 16 Oct 2025.